A randomized controlled study of effectiveness between transcatheter arterial chemoembolization with fine powder cisplatin (IA-call) and transcatheter chemoembolization with Miriplatin for unresectable hepatocellular carcinomas(multicenter clinical trial PhaseII) - Comparative study between CDDP-TACE and Miriplatin-TACE for unresectable HCC.

Japan community health care organization hitoyoshi medical center0 个研究点目标入组 100 人开始时间: 2011年4月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Tumor thrombus in the main portal vein(VP4). 2) Remarkable arterio-portal shunt and arterio-venous shunt. 3) Uncontrollable ascites or pleural effusion. 4) Previous medical history of severe hypersensitivity. 5) Previous history of treatment using Cisplatin(IA-call) or Miriplatin(MILIPLA). 6) Serious complications as described below (Except chronic hepatitis and liver cirrhosis) i) Severe heart disease ii) Myocardial infarction within 6months iii) Renal failure iv) Active infection except viral hepatitis v) Active bleeding from the digestive tract vi) Another active cancers (besides hepatocellular carcinoma, the double cancers which can decide the prognosis). vii) Hepatic encephalopathy or severe psychiatric disease. 7) Pregnant women and women suspected of being pregnant. 8) Patients who are concluded to be inappropriate to participate in this study by the lead investigator and other physicians in charge.

发起方

Japan community health care organization hitoyoshi medical center